Skip to content
Menu

Vivos Therapeutics, Inc. VVOS

Full chart Compare
Set alert

Price alert · VVOS

All alert types
0.05 USD 0.00 (-5.10%)

Regular-session close

0.05 0.00 -3.70%

After hours · Nov 20, 7:46 PM ET

0.0501 Day range 0.0568
0.0501 52-week range 2.69
YTD
-97.34%
1 year
-97.45%

5D -0.0124 (-13.11%)

0.08000.09000.1000TueWedThuFriMon0.0822
Market cap
1.83M
Revenue (ttm)
14.02M
Profit margin
-85.90%
EPS (ttm)
-1.35
Shares out
4.84M
Forward P/E
-9.31
YTD return
-97.34%
1-year return
-97.45%
Volume
1.44M
Avg volume
14.42M
Open
0.0535
Previous close
0.0569
Day's range
0.0501 – 0.0568
52-week range
0.0501 – 2.69
Beta
7.68
Price target
6.30 (+11566.7%)

Key statistics

50-day average
3.32
200-day average
2.88
Enterprise value
4.52M
Price / sales
1.77
Price / book
22.86
Revenue growth
19.40%
Free cash flow
-8.90M
Total cash
6.90M
Total debt
1.76M
Return on equity
-284.96%
Short % of float
2.01%

Fundamental scorecard

6 of 25 checks passed on VVOS’s reported financials

ValueGrowthProfitabilityHealthDividend

6of 25 checks passed

  • Value 2 of 5
  • Growth 3 of 5
  • Profitability 1 of 5
  • Financial health 0 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
VVOS Revenue — quarterly 6.41M
VVOS Net income — quarterly -1.95M
VVOS EPS — quarterly -0.07

Earnings

VVOS recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 14, 2024Sep 1, 2024-0.70-0.40+0.30+42.86%
Aug 14, 2024Jun 1, 20240.00-0.60——
Aug 14, 2024Jun 1, 20240.00———
May 14, 2024Mar 1, 20240.00-1.63——
May 14, 2024Mar 1, 20240.00———
Mar 28, 2024Dec 1, 20230.00-3.05——

Upgrades / downgrades

VVOS analyst upgrades and downgrades
DateFirmActionFromTo
Nov 20, 2024Ascendiant CapitalreitBuyBuy
Nov 19, 2024Alliance Global PartnersmainBuyBuy
Aug 20, 2024Ascendiant CapitalmainBuyBuy

About Vivos Therapeutics, Inc.

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.

Sector
Healthcare
Industry
Medical Devices
Country
United States
Website
vivos.com

News

Your note

Sign in to keep a note on VVOS — it syncs with the Stock Master app.

Insider holders

VVOS insider holders
InsiderRelationLatest transactionDateShares held
HUNTSMAN RONALD KIRKChief Executive OfficerPurchaseJun 19, 20231,826,520

Institution ownership

VVOS institution ownership
Holder% heldSharesValueReported
Strategic Wealth Investment Group, LLC2.07%100,000512.00KSep 29, 2024
Geode Capital Management, LLC0.60%28,802147.47KSep 29, 2024
OMERS Administration Corporation0.52%25,000128.00KSep 29, 2024
Commonwealth Equity Services, LLC0.43%21,000107.52KSep 29, 2024
Sabby Management, LLC0.42%20,502104.97KSep 29, 2024
Two Sigma Investments, LP0.42%20,482104.87KSep 29, 2024

Fund ownership

VVOS fund ownership
Holder% heldSharesValueReported
Fidelity Extended Market Index Fund0.38%18,24793.42KOct 30, 2024
Vanguard Extended Market Index Fund0.22%10,57954.16KSep 29, 2024
Fidelity Total Market Index Fund0.12%5,82529.82KOct 30, 2024
Fidelity Series Total Market Index Fund0.12%5,66729.02KOct 30, 2024